MXPA04005210A - Process for the prereparation of compositions having an increased amount of pharmaceutically active salts of rotamers. - Google Patents

Process for the prereparation of compositions having an increased amount of pharmaceutically active salts of rotamers.

Info

Publication number
MXPA04005210A
MXPA04005210A MXPA04005210A MXPA04005210A MXPA04005210A MX PA04005210 A MXPA04005210 A MX PA04005210A MX PA04005210 A MXPA04005210 A MX PA04005210A MX PA04005210 A MXPA04005210 A MX PA04005210A MX PA04005210 A MXPA04005210 A MX PA04005210A
Authority
MX
Mexico
Prior art keywords
rotamers
prereparation
compositions
pharmaceutically active
increased amount
Prior art date
Application number
MXPA04005210A
Other languages
Spanish (es)
Inventor
David J S Tsai
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04005210A publication Critical patent/MXPA04005210A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

In one embodiment, the present invention discloses a process to directly prepare an unequal ratio of rotamers of an acid salt from a basic compound, by creative choice of a solvent medium. The process is particularly useful in preparing specific rotamers of pharmaceutically useful salts in desired preponderance.
MXPA04005210A 2001-11-29 2002-11-26 Process for the prereparation of compositions having an increased amount of pharmaceutically active salts of rotamers. MXPA04005210A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33433101P 2001-11-29 2001-11-29
US37391602P 2002-04-19 2002-04-19
PCT/US2002/038112 WO2003048153A1 (en) 2001-11-29 2002-11-26 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers

Publications (1)

Publication Number Publication Date
MXPA04005210A true MXPA04005210A (en) 2004-08-19

Family

ID=26989151

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005210A MXPA04005210A (en) 2001-11-29 2002-11-26 Process for the prereparation of compositions having an increased amount of pharmaceutically active salts of rotamers.

Country Status (12)

Country Link
US (2) US6943251B2 (en)
EP (1) EP1451174B1 (en)
JP (2) JP2005511693A (en)
CN (1) CN1596254A (en)
AR (1) AR037679A1 (en)
AT (1) ATE478065T1 (en)
AU (1) AU2002346569A1 (en)
CA (1) CA2468525A1 (en)
DE (1) DE60237388D1 (en)
HK (1) HK1063798A1 (en)
MX (1) MXPA04005210A (en)
WO (1) WO2003048153A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
EP1451174B1 (en) * 2001-11-29 2010-08-18 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
CN100396676C (en) * 2002-03-29 2008-06-25 先灵公司 Synthesis of piperidine and piperazine compounds as CCR5 antagonists
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US7521452B2 (en) 2005-01-06 2009-04-21 Schering Corporation Preparation of pharmaceutical salts of piperazine compounds
WO2007038496A2 (en) * 2005-09-27 2007-04-05 Chemic Laboratories, Inc. Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers
US7561458B2 (en) * 2006-12-26 2009-07-14 Texas Instruments Incorporated Ferroelectric memory array for implementing a zero cancellation scheme to reduce plateline voltage in ferroelectric memory
SG183133A1 (en) 2010-03-11 2012-09-27 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
WO2015200635A1 (en) * 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2299206C9 (en) * 1999-05-04 2007-11-20 Шеринг Корпорейшн Derivatives of piperazine, pharmaceutical compositions containing thereof and using as ccr5 antagonists
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
JP3874229B2 (en) 1999-07-02 2007-01-31 Ｔｄｋ株式会社 Piezoelectric ceramics and piezoelectric device using the same
EP1451174B1 (en) * 2001-11-29 2010-08-18 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers

Also Published As

Publication number Publication date
DE60237388D1 (en) 2010-09-30
WO2003048153A1 (en) 2003-06-12
EP1451174B1 (en) 2010-08-18
US20050171117A1 (en) 2005-08-04
ATE478065T1 (en) 2010-09-15
US20030144510A1 (en) 2003-07-31
AU2002346569A1 (en) 2003-06-17
US7534884B2 (en) 2009-05-19
EP1451174A2 (en) 2004-09-01
JP2010132705A (en) 2010-06-17
CN1596254A (en) 2005-03-16
HK1063798A1 (en) 2005-01-14
CA2468525A1 (en) 2003-06-12
JP2005511693A (en) 2005-04-28
WO2003048153A8 (en) 2004-06-03
AR037679A1 (en) 2004-12-01
AU2002346569A8 (en) 2003-06-17
US6943251B2 (en) 2005-09-13

Similar Documents

Publication Publication Date Title
MXPA02007819A (en) Crystalline salts of 7 [4 (4 fluorophenyl) 6 isopropyl 2 [methyl(methylsulfonyl )amino]pyrimidin 5 yl] (3r,5s) 3,5 dihydroxyhept 6 enoic acid.
YU70901A (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
WO2001017972A3 (en) Novel herbicides
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
BR0108893B1 (en) pharmaceutical composition containing azetidine derivatives, azetidine derivative compound, and process for the preparation of compounds.
AU2002239344A1 (en) Pyrazolopyridines
MXPA02003977A (en) INHIBITORS OF agr;L.
WO2001017973A3 (en) Novel herbicides
MXPA03011954A (en) Novel sulfonic acid derivatives.
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
CA2496623A1 (en) Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
HK1076816A1 (en)
MXPA04005210A (en) Process for the prereparation of compositions having an increased amount of pharmaceutically active salts of rotamers.
WO2002020017A3 (en) Use of ectoin or ectoin derivatives for stabilizing p53
BR0206730A (en) Process for preparing a non-hygroscopic sodium valproate composition, a non-hygroscopic pharmaceutical composition and its use
EP1555261A4 (en) Valerolactone compounds and perfume composition
TR200200745T2 (en) Process for phenylacetic acid derivatives.
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
HRP20010798B1 (en) Processes for preparing pesticidal intermediates
CA2434408A1 (en) Process for the preparation of heterocyclic indene analogs
EP1390343A4 (en) Novel retinoid derivatives and methods for producing said compounds and an anti-cancer pharmaceutical composition comprising said compounds
AU2001282238A1 (en) Dihydroporphyrin derivatives and their uses
ATE427934T1 (en) NON-PEPTIDIC BRS-3 AGONISTS
GB0103046D0 (en) Organic Compounds
CA2425368A1 (en) New sulphoxybenzamides

Legal Events

Date Code Title Description
FG Grant or registration